DCAT Welcomes Three New Member Companies
Robbinsville, NJ, March 29, 2010 – The Drug, Chemical and Associated Technology Association (DCAT), the PharmaChem industry’s premier business development association, is pleased to announce the addition of the following new member companies: Amerigen Pharmaceuticals, Inc., Halo Pharmaceutical, and Liptis Pharmaceuticals USA, Inc. To learn about other DCAT member companies, visit DCAT’s Meet Our Members.
Amerigen Pharmaceuticals, Inc.
Amerigen is a multinational pharmaceutical company with low-cost development and manufacturing platforms aimed at providing high-quality generic pharmaceutical products. With pharmaceutical assets abroad and science-based expertise in the United States, Amerigen is able to provide quality products at competitive prices along with excellent customer service. www.amerigenpharma.com
Halo is a full service contract development and commercial manufacturing company based in New Jersey and capable of supporting a wide range of pharmaceutical drug product dosage forms from Phase 1 through commercial product lifecycle extension activities. www.halopharma.com
Liptis Pharmaceuticals USA, Inc.
Liptis Pharmaceuticals provides high quality, value based pharmaceuticals and nutraceuticals to meet the healthcare needs of patients in emerging markets. As a U.S.-based manufacturer and marketer of innovative brand and branded generic products, we continue to grow our portfolio through strategic alliances and partnerships; we constantly welcome new opportunities that can add mutual value.
DCAT is the premier business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical, nutritional and related industries.
DCAT Communications Coordinator